Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community
Adam J. Nelson(Clinical Research Institute), Christopher B. Granger(Clinical Research Institute), Vanita R. Aroda(Brigham and Women's Hospital), Melissa Magwire(Saint Luke's Health System), Jennifer B. Green, Rodica Pop‐Busui(University of Michigan), Jonathan Pak(Boehringer Ingelheim (United States)), Lisa A. Kaltenbach(Duke University), Çağrı Şenyücel(Eli Lilly (United States)), Caroline R. Richardson(Brown University), Julienne K. Kirk(Wake Forest University), Renato D. Lópes(Duke University), Hussein R. Al‐Khalidi(Clinical Research Institute), Darren K. McGuire(Parkland Health & Hospital System), Monica C. Reed(Clinical Research Institute), Matthew A. Cavender, Emily C. O’Brien(Duke University), Neha J. Pagidipati(Duke University), Ildiko Lingvay(Southwestern Medical Center), Laura Webb(Duke University), Tanya Gaynor(Boehringer Ingelheim (United States))
Cited by 79
Related Papers
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
|New England Journal of Medicine|2023|2.6k
2. Classification and Diagnosis of Diabetes:<i>Standards of Care in Diabetes—2023</i>
|Diabetes Care|2022|2.4k
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2017|2.1k